Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo ...

With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Other notable outperformers include FDC (9.5%), Eris Lifesciences Ltd. (8.6%), Alkem Laboratories Ltd. (7.2%), Abbott India ...

€400 million upfront payment from restructured GSK collaboration reflected in financials ... of senior corporate and investment banking experience within the biotech and pharmaceutical industries.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Stocks like Chambal Fertilisers and Chemicals, Gujarat Gas, Hindalco Industries,India Pesticides, Kirloskar Ferrous ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...